| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human BTLA-C-His-Avi protein was developed from hek293 and has a target region of C-His-Avi. For use in research applications. |
| Conjugation: |
Biotin |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: |
Upon receipt centrifuge vial to ensure maximal product extraction, recommended: 20sec, 5K RPM |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). |
| Gene Symbol: |
BTLA |
| Gene ID: |
151888 |
| Uniprot ID: |
BTLA_HUMAN |
| Immunogen Region: |
Lys31-Ser150 |
| Immunogen: |
DNA sequence encoding Human BTLA including a C-His-Avi tag was expressed in HEK293 Cells. The recombinant protein was then biotinylated site specific using the AVItag biotinylation technology. |
| Function | Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells. |
| Protein Name | B- And T-Lymphocyte AttenuatorB- And T-Lymphocyte-Associated ProteinCd Antigen Cd272 |
| Database Links | Reactome: R-HSA-388841 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
| Alternative Protein Names | B- And T-Lymphocyte Attenuator proteinB- And T-Lymphocyte-Associated Protein proteinCd Antigen Cd272 proteinBTLA protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
